Syeda Najidah Shahni

Syeda Najidah Shahni

Auto-generated profile, based on publicly available information

Syeda Najidah Shahni

Multidisciplinary Centre for Advanced Research and Studies, Jamia Millia Islamia, New Delhi, India

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Journal of Nucleic Acids
Verified
Journal Article
Open access
SSSyeda Najidah Shahni
Syeda Najidah Shahni
SASarah Albogami
Sarah Albogami
IAIqbal Azmi
Iqbal Azmi
BPBijay Pattnaik
Bijay Pattnaik
RCRituparna Chaudhuri
Rituparna Chaudhuri
TATanvir Ahmad
Tanvir Ahmad
The development of sensitive and specific diagnostic tools for hepatitis B virus (HBV) and hepatitis C virus (HCV) remains crucial for effective disease management and control. In this study, we utilized CRISPR‐Cas12 and CRISPR‐Cas13 systems for the detection of HBV (DNA virus) and HCV (RNA virus), respectively. We designed and tested multiple guide RNAs (gRNAs) targeting both viruses, confirming successful cleavage of target sequences through gel electrophoresis and a fluorescent reporter assay. Using optimized gRNAs, we developed a lateral flow assay (LFA) for sensitive detection of HBV and HCV, demonstrating a concentration‐dependent signal increase. Importantly, no cross‐reactivity was observed with other viral targets. To further enhance sensitivity, we employed a dual‐enzyme approach, combining Cas12 and Cas13 in a single reaction, which significantly improved detection limits for both viruses. Finally, we developed a dual antigen detection LFA strip capable of simultaneously detecting both HBV and HCV in a single sample. This approach holds promise for point‐of‐care (POC) diagnostics where the specific viral infection is unknown. This study addresses the current limitations in CRISPR‐Cas based diagnostics, namely, the need for ultrasensitive detection methods and the ability to detect multiple antigens using a single test strip. Our findings demonstrate the feasibility of using CRISPR‐Cas systems for highly sensitive and specific detection of HBV and HCV, paving the way for potential POC application.